These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30171552)

  • 21. Use of Glucose-Fructose to Enhance the Exon Skipping Efficacy.
    Han G; Gao X; Yin H
    Methods Mol Biol; 2018; 1828():327-342. PubMed ID: 30171551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
    Relizani K; Goyenvalle A
    Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.
    Aoki Y; Nakamura A; Yokota T; Saito T; Okazawa H; Nagata T; Takeda S
    Mol Ther; 2010 Nov; 18(11):1995-2005. PubMed ID: 20823833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy.
    Jirka SMG; 't Hoen PAC; Diaz Parillas V; Tanganyika-de Winter CL; Verheul RC; Aguilera B; de Visser PC; Aartsma-Rus AM
    Mol Ther; 2018 Jan; 26(1):132-147. PubMed ID: 29103911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic Antisense Therapeutics for Dystrophin and Myostatin Exon Splice Modulation Improve Muscle Pathology of Adult mdx Mice.
    Lu-Nguyen N; Malerba A; Popplewell L; Schnell F; Hanson G; Dickson G
    Mol Ther Nucleic Acids; 2017 Mar; 6():15-28. PubMed ID: 28325281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse.
    Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Steinhaus JP; Moulton HM; Iversen PL; Wilton SD
    Mol Ther; 2007 Sep; 15(9):1587-92. PubMed ID: 17579573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing RNA/ENA chimeric antisense oligonucleotides using in vitro splicing.
    Takeshima Y; Yagi M; Matsuo M
    Methods Mol Biol; 2012; 867():131-41. PubMed ID: 22454059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.
    Anthony K; Feng L; Arechavala-Gomeza V; Guglieri M; Straub V; Bushby K; Cirak S; Morgan J; Muntoni F
    Hum Gene Ther Methods; 2012 Oct; 23(5):336-45. PubMed ID: 23075107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development.
    Wu B; Benrashid E; Lu P; Cloer C; Zillmer A; Shaban M; Lu QL
    PLoS One; 2011; 6(5):e19906. PubMed ID: 21611204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.
    Mann CJ; Honeyman K; Cheng AJ; Ly T; Lloyd F; Fletcher S; Morgan JE; Partridge TA; Wilton SD
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):42-7. PubMed ID: 11120883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Vivo Administration of Splice Switching PNAs Using the mdx Mouse as a Model System.
    Brolin C; Lim EWK; Nielsen PE
    Methods Mol Biol; 2020; 2105():241-250. PubMed ID: 32088875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.
    Yin H; Lu Q; Wood M
    Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
    Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
    Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.
    van Deutekom JC; Bremmer-Bout M; Janson AA; Ginjaar IB; Baas F; den Dunnen JT; van Ommen GJ
    Hum Mol Genet; 2001 Jul; 10(15):1547-54. PubMed ID: 11468272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle.
    Arechavala-Gomeza V; Graham IR; Popplewell LJ; Adams AM; Aartsma-Rus A; Kinali M; Morgan JE; van Deutekom JC; Wilton SD; Dickson G; Muntoni F
    Hum Gene Ther; 2007 Sep; 18(9):798-810. PubMed ID: 17767400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.